AI Inc (CSE: TRUE) Partners with Novus Health to Support Over 1.5 Million Members and Families

May 16 05:12 2024 AI Inc (CSE: TRUE) Partners with Novus Health to Support Over 1.5 Million Members and Families
HealthCare AI Stocks
Dr. Essam Hamza, CEO of Treatment, comments: “We are very excited to partner with a recognized leading healthcare firm in Novus Health. There is a near term opportunity to implement our proprietary AI diagnostic tools into the solutions offered to their vast customer base. However, with this collaboration we also have an opportunity to extend into new mutually developed tools and solutions that have the ability to further improve health care efficiency and patient outcomes.”

In recent years, artificial intelligence (AI) has begun to revolutionize various sectors, but its impact on healthcare is particularly profound. As technology advances, AI’s potential to transform medical practices and patient outcomes is becoming increasingly evident. A shining example of this technological progression is the new collaborative agreement between AI Inc. and Novus Health.

Pioneering AI in Healthcare: The AI and Novus Health Partnership

On May 15, 2024, AI Inc. (CSE: TRUE), announced a significant partnership with Novus Health, a company renowned for its health navigation services supporting over 1.5 million members. This collaboration aims to harness AI’s proprietary Global Library of Medicine (GLM) to enhance Novus Health’s Health Risk Assessment programs.

The GLM, developed over seven years with inputs from hundreds of global healthcare professionals, represents one of the world’s most sophisticated AI healthcare engines. It provides precise, personalized healthcare diagnostics driven by proprietary algorithms, offering more than 92% accuracy on initial diagnoses. This tool not only suggests possible diagnoses but also recommends tests, X-rays, and even billing codes, all while explaining each step of the diagnostic process.

The Scope and Potential of the Collaboration

The agreement between AI and Novus Health is not just a merger of tools and services but a strategic alignment that seeks to innovate continually. Dr. Essam Hamza, CEO of Treatment, emphasized the near-term opportunities to integrate their AI diagnostic tools with Novus Health’s vast customer base. Moreover, this partnership opens doors to developing new tools that could significantly enhance healthcare efficiency and patient outcomes.

Jamie Marcellus, CEO of Novus Health, also expressed enthusiasm about integrating AI’s capabilities into their services. He highlighted how AI could bring unparalleled efficiency and accuracy to health risk assessments, facilitating quicker and more informed decision-making that could preemptively address health threats.

Implications for the Health Insurance Market and Beyond

This collaboration also intends to test, develop, and potentially commercialize novel solutions that could proactively impact the health insurance market. By leveraging AI, the partnership can offer more predictive insights, leading to better risk management and more personalized patient care strategies.

A Step Towards Future Healthcare Innovations

The partnership between AI and Novus Health is a testament to the revolutionary potential of AI in healthcare. By integrating sophisticated AI tools into health assessment and risk management, the alliance not only aims to improve current healthcare delivery but also paves the way for future innovations that could transform the health sector globally.

As AI continues to advance, its integration into healthcare promises not only more efficient and accurate diagnoses but also a new era of personalized medicine that could extend beyond traditional medical practices to encompass holistic health management and preventive care. This collaboration is just the beginning of what may be a significant shift towards an AI-enhanced approach to healthcare.

Today’s stock market saw significant movement among top gainers. Leading the charge was Selina Hospitality (NASDAQ: SLNA), which surged by 195.18%, closing at $0.17 with a market cap of $428.03 million. SINTX Technologies (NASDAQ: SINT) followed closely, jumping 176.36% to $0.15, boasting a market cap of $931.11 million. Faraday Future Intelligent Electric (NASDAQ: FFIE) also made headlines with a 156.08% increase, reaching $0.73 and a market cap of $1.28 billion. AERWINS Technologies (AWIN) rose by 135.79%, ending at $6.39 and a market cap of $48.17 million. Additionally, Reborn Coffee (NASDAQ: REBN) climbed 44.66% to $3.66, with a market cap of $410.50 thousand, and T2 Biosystems (NASDAQ: TTOO) gained 44.23%, closing at $6.00 with a market cap of $3.01 million.

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.


Media Contact
Company Name: TheBullReport
Contact Person: Ward Abbott
Email: [email protected]
City: Dallas
State: Texas
Country: United States

view more articles

About Article Author